Physician profile
Jade Bryant
NPI 1154861995
$1,936.66
in general payments reported to CMS, 2019-2025
22 companies · $326 in 2025
The $326 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $294 · 2022: $310 · 2023: $545 · 2024: $462 · 2025: $326.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,333.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,333.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $684.97 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $273.02 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Neurocrine Biosciences, INC. | $155.60 | 2021-2024 | Ingrezza |
| Lilly USA, LLC | $100.97 | 2021-2024 | Mounjaro, Emgality, Reyvow |
| Axsome Therapeutics, INC. | $95.85 | 2024-2025 | Auvelity, Symbravo |
| Astrazeneca Pharmaceuticals LP | $95.36 | 2021-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $63.01 | 2022-2024 | Caplyta |
| Novo Nordisk INC | $61.07 | 2024-2025 | Rybelsus, Ozempic |
| Amgen INC. | $47.67 | 2021-2023 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $44.69 | 2021 | |
| Genzyme Corporation | $41.68 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $38.06 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $38.06 | 2021 | |
| Pfizer INC. | $34.43 | 2023 | |
| Idorsia Pharmaceuticals US INC | $32.11 | 2023 | Quviviq |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $29.13 | 2023 | Yupelri |
| Corcept Therapeutics | $22.93 | 2024 | Korlym |
| Nevro Corp. | $19.40 | 2023 | Senza |
| Biohaven Pharmaceutical Holding Company LTD. | $16.85 | 2022 | |
| Exact Sciences Corporation | $16.33 | 2025 | Cologuard Collection Kit |
| Scilex Pharmaceuticals INC. | $13.70 | 2021 | |
| Eisai INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jade Bryant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.